CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)

NCT04933422 · clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
72
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Crimson Biopharm Inc.